Viking Therapeutics Inc

VKTX is in a Stage 2 acceleration phase, marked by a parabolic rally but facing extreme overbought and exhaustion signals. The medium-term bias remains bullish given the continuation pattern and rising moving averages, yet short-term timing is unfavorable. We recommend stalking pullbacks into the rising EMAs or prior breakout zone for a more favorable entry.

• ↑Initiated Phase 1 trial for VK3019 dual amylin/calcitonin obesity therapy.
• ↑Stock up 17.5% in 7 days and 43.6% over past year.
• ↓Negative earnings yield and poor profitability metrics suggest overvaluation risk.